A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food

Status:
Completed

Trial end date:
2013-11-01

Target enrollment:

Participant gender:

The purpose of this study is to examine the exposure and safety of a supratherapeutic dose of PCI-32765 (ibrutinib) in healthy adult volunteers.

Phase 1

Janssen Research & Development, LLC

Pharmacyclics LLC.

Pharmaceutical Solutions